Abilify and Dose
Links shared publicly online about this topic
Comments of using Wellbutrin Xl, Abilify, Concerta (study 6192781) - eHealthMe.com
ehealthme.com — “My son has been taking high doses of Concerta XR 3 36mg pills every morning for 5-10 years and he was recently diagnosed with Lesions on his brain. He was having memory loss and losing IQ. Could this medicine have caused a stroke at such high doses?” View full resource at ehealthme.com
Most Recently Shared on March 26, 2012 at 5:36 am By:
My son has been taking high doses of Concerta XR 3 36mg pills every morning for 5-10 years and he was recently http://t.co/wWVROaRr
A placebo-controlled, fixed-dose study of aripipra... [J Am Acad Child Adolesc Psychiatry. 2009] - PubMed result
ncbi.nlm.nih.gov — “PubMed is a service of the U.S. National Library of Medicine that includes over 18 million citations from MEDLINE and other life science journals for biomedical articles back to the 1950s. PubMed includes links to full text articles and other related resources.” View full resource at ncbi.nlm.nih.gov
Most Recently Shared on October 3, 2009 at 2:38 pm By:
William Yates, M.D. Psychiatrist, Family Medicine Doctor, Physician, and Doctor
Aripiprazole (Abilify) reduces irritability in adolescents with autism in clinical trial. http://ow.ly/swv6
OpEdNews - Article: Tracking the American Epidemic of Mental Illness - Part II
opednews.com — “A fortune can be made from these life-long antipsychotic customers. In April 2010, the price for one box of Invega, at a middle dose, was $1,373 at DrugStore.com. Risperdal went for $788 per 90 pills. The cost was $1,395 for 100 tablets of Abilify. Seroquel cost $997 per 100. One-hundred capsules of Geodon sold for $918 and Zyprexa cost $1,523 for a hundred 10mg pills.” View full resource at opednews.com
Most Recently Shared on June 3, 2010 at 5:38 am By:
Peter H Brown Doctor and Psychologist
Tracking the American Epidemic of Mental Illness - Part II http://bit.ly/cQtglM #psychosis #schizo
Alkermes Announces Positive Results From Clinical Study Of ALKS 9070 For Treatment Of Schizophrenia - QualityPoint Technologies
qualitypointtech.net — “Alkermes, Inc. (NASDAQ: ALKS) today announced positive topline results from a phase 1b, double-blind, randomized, placebo-controlled study of ALKS 9070 in patients with schizophrenia. ALKS 9070, a proprietary Alkermes molecule for the treatment of schizophrenia, is designed to provide patients with once-monthly dosing of a medication that, once in the body, converts into aripiprazole, a molecule that is commercially available under the name ABILIFY® for the treatment of a number of central nervo” View full resource at qualitypointtech.net
Most Recently Shared on July 1, 2011 at 6:00 pm By:
Alkermes Announces Positive Results From Clinical Study Of ALKS 9070 For Treatment Of Schizophrenia: Alkermes, Inc... http://bit.ly/kd2y2o
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
eHealthMe.com
eHealthMe provides health professionals and patients personalized tools to study millions of drug reports from FDA and community in real time.
-
William Yates, M.D.
Clinical Neuroscientist. Research Psychiatrist, Laureate Institute of Brain Research (laureateinstitute.org) Professor of Research, University of Oklahoma.
-
Peter H Brown
Peter H Brown Clinical Psychologist. I'm also a Husband & Dad & wannabe techno-junkie
Advertisement
